Newsletter sign up



Copyright 2017
Terms & Conditions


About Peter Hofland
About Peter Hofland Peter Hofland, Ph.D is the Executive Editor of ADC Review/Journal of Antibody-drug Conjugates, a comprehensive digital platform and peer reviewed publication focusing on news and information about innovative therapies such as Antibody-drug Conjugates (ADCs). Hofland contributes articles on the advances in ADCs - from initial discovery to approved drug. He is also a contributor to Onco'Zine and The Onco'Zine Brief.

Articles by Peter


New Hybrid Cancer Center Model Helps Meet the Demand for Better Quality Care

Published on 27th November

A new cancer center model is helping meet the demand for better quality cancer care in community settings, and ADC Review | Journal of Antibody-drug Conjugates has an original paper describing the concept. [1]

Hybrid academic-community cancer centers began emerging and evolving at several sites in some southern and mid-Atlantic states during the last several years, and in February 2017 a number of their directors, and other key members of their respective institutions, gathered for a CME-sponsored full-day workshop in Miami to share experiences and best practices to advance the model.

Cancer centers qualified to be classified as hybrid academic-community cancer centers shared the following attributes:

  • Most recruited respected academic-clinician leaders from NCI-designated comprehensive cancer centers.
  • They were established at large, well-respected, financially secure not-for-profit regional community hospital systems interested in increasing quality of care and standards of practice.
  • They sought to infuse greater academic rigor into their programs, develop translational research programs, enroll more patients from their respective communities into clinical trials, and provide the best cancer care to populations not served by traditional academic centers.
  • They often adapted existing resources through collaborative efforts rather than reinventing the wheel.

The centers represented were Baptist Health South Florida’s Miami Cancer Institute, Miami, Fla.; West Cancer Center, Memphis, Tenn.; Inova Schar Cancer Institute, Falls Church, Va.; and Gibbs Cancer Center and Research Institute, Spartanburg Regional Healthcare System, Spartanburg, SC.

Participants discussed how and why their centers were created, academic partnerships, future goals, and opportunities and challenges in research, treatment, recruitment, marketing, and fundraising, among other issues.

The conference was organized and moderated by Onco’Zine editor-at-large Eric T. Rosenthal, who first identified, named, and described the concept in a series of articles appearing in MedPage Today in 2015.

The article “The Nature and Nurturing of Hybrid Academic-Community Cancer Centers,” was co-authored by Rosenthal and the cancer center directors, Michael Zinner, MD, Lee Schwartzberg, MD, Donald L. “Skip” Trump, MD, and Timothy Yeatman, MD and was published today in ADC Review | Journal of Antibody-drug Conjugates.


Last Editorial Review: November 27, 2017

Featured Image: Hybrid Academic-Community Cancer Center. Courtesy: © Fotolia | Used with permission.

Copyright © 2017 Sunvalley Communication, LLC. All rights reserved. Republication or redistribution of Sunvalley Communication content, including by framing or similar means, is expressly prohibited without the prior written consent of Sunvalley Communication. Sunvalley Communication shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Onco’Zine, Oncozine and The Onco’Zine Brief are registered trademarks and trademarks of Sunvalley Communication around the world.


Print Friendly, PDF & Email

Leave a Reply

Your email address will not be published. Required fields are marked *